

Application No. 10/569,583
Amendment Dated 12 January 2007
Reply to Office Action of 12 December 2006

Remarks/Arguments:

Applicants are filing herein an amended set of claims in response to the restriction requirement dated 12 December 2006.

Applicants respectfully point out to the Examiner that claims 1-23 are not pending in the application (as stated in the Office Action Summary) – claims 10, 13 and 14 were cancelled in the Preliminary Amendment filed February 23, 2006.

Applicants respectfully disagree with the Examiners assessment of the claims, in particular the relevance of cited document US 5,763,429. However, in order to expedite prosecution of this application Applicants elect Group II (claim(s) 2, 9, drawn to a combination comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and a bisphosphonate) without traverse.

As the single species, Applicants elect pamidronic acid.

Applicants have amended the claims accordingly. Note, however, we have retained claim 11, changing the dependency accordingly. Furthermore, new claims 24-28 have been added. Basis for this amendment is to be found on page 7, lines 17-22.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101213-1P US.

Respectfully submitted,

/Lucy Padget/

Name: Lucy Padget
Dated: 12 January 2007
Reg. No.: L0074
Phone No.: 781-839-4182
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham, MA 02451